Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
841-860 of 936 trials

Cholesterol Management: Fixed Dose Combination Study

We are evaluating a new combination pill of bempedoic acid, ezetimibe, and atorvastatin for patients managing high cholesterol. The goal is to see if this combination works as well as taking each medication separately.

Healthy Participants≤3 monthsSafety phase (I)CardiologyInternal Medicine

ALS Treatment: EH-301 and N-Acetylcysteine with Riluzole

We are studying a new combination therapy for people with ALS to see if it can slow disease progression and improve muscle strength and quality of life. This trial compares the treatment to a placebo to evaluate its effectiveness.

Amyotrophic Lateral Sclerosis (ALS)1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

PM14 Treatment for Soft Tissue Sarcomas and Solid Tumors

We are studying how PM14 works alone and with radiotherapy in patients with soft tissue sarcomas and other solid tumors. The goal is to find the best treatment approach and understand its safety and effectiveness.

Soft Tissue Sarcomas and Other Solid Tumors6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

THN391 for Early Alzheimer's Disease

We are testing a new medication to see if it is safe and well-tolerated in people with early Alzheimer's disease. This study will help us understand how the drug works in the body.

Alzheimer's Disease1-2 yearsSafety phase (I)Neurology

High-Risk Essential Thrombocythaemia: STP938 Treatment Study

We are evaluating a new medication for adults with high-risk essential thrombocythaemia who have not tolerated or responded to standard treatment. The study aims to assess its safety and early effects.

Essential Thrombocythaemia>2 yearsSafety phase (I)Hematology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Kidney Transplant: Autologous Tolerogenic Dendritic Cells

We are testing a new treatment using patients' own immune cells to help highly sensitized kidney transplant recipients accept their new organ. This study aims to improve transplant success rates for these individuals.

Kidney Transplant>2 yearsSafety phase (I)NephrologyUrology

FT751: Safety and Tolerability Study

We are examining a new oral medication, FT751, in healthy individuals to understand its safety and how it is processed in the body. This research may help inform future treatments.

Autoimmune Disorders6-12 monthsSafety phase (I)Rheumatology

Cancer Treatment: NTX-1088 and Pembrolizumab

We are studying the effects of NTX-1088 alone and with Pembrolizumab in patients with cancer. The goal is to see if this combination improves treatment outcomes.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Stem Cell Transplant: New T Cell Therapy

We are studying a new treatment using special T cells to help prevent complications in patients receiving stem cell transplants from siblings. The goal is to see if this approach can safely reduce the need for other medications.

Healthy Participants6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal Medicine

Brain Disorders: NT 0150 Study

We are investigating a new compound, NT 0150, for its safety and how it is absorbed and eliminated in the body. This research may help in developing treatments for Alzheimer's and Parkinson's disease.

Cryopyrin Associated Periodic Syndrome6-12 monthsSafety phase (I)Internal MedicineNeurology

Rheumatoid Arthritis: Study of PIT565

We are testing a new treatment called PIT565 for individuals with rheumatoid arthritis. The study aims to understand its safety and how the body processes it.

Rheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

WVE-007 for Adults with Overweight or Obesity

We are testing a new treatment called WVE-007 to see how it affects adults living with overweight or obesity. This study aims to understand its safety and how it may help with weight management.

Overweight and Obesity in Adults1-2 yearsSafety phase (I)EndocrinologyInternal Medicine

Metastatic Esophagogastric Cancer: MT-302 with CapOx

We are investigating the safety and early effectiveness of a new treatment, MT-302, combined with CapOx chemotherapy for patients with metastatic esophagogastric cancer.

Metastatic Esophagogastric Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

MK-7228: A New Medication Study

We are investigating the effects of MK-7228 in healthy men to understand its safety and how it works. This research may help inform future treatments.

Atherosclerosis1-2 yearsSafety phase (I)CardiologyInternal Medicine

Type 2 Diabetes: Insulin NNC0471-0119 via Pump

We are studying how a new insulin works in people with type 2 diabetes when delivered through an insulin pump. This research may help improve diabetes management.

Type 2 Diabetes6-12 monthsSafety phase (I)DiabetologyEndocrinology

Liver Health: Lepodisiran Study

We are studying how a single dose of Lepodisiran affects people with varying degrees of liver impairment and those with normal liver function. This research may help us understand the medication's safety and effectiveness in different liver conditions.

Liver ImpairmentSafety phase (I)HepatologyInternal Medicine

PF-07999415: Tolerance Study in Healthy Adults

We are investigating how well different amounts of the medicine PF-07999415 are tolerated by healthy adults. This study will help us understand its effects in the body.

Metabolism and Nutrition Disorders6-12 monthsSafety phase (I)EndocrinologyInternal Medicine

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

REM0045392: New Medication Study

We are investigating a new medication to see how safe and effective it is compared to a placebo in healthy individuals. This study will help us understand its potential benefits and risks.

Alzheimer's Disease1-2 yearsSafety phase (I)Neurology